The optimal treatment for use as a bridge to allogeneic hematopoietic stem cell
transplantation at the decision for transplantation has not been established in patients with …

Background Recent data suggest that, among other factors, comorbidity may be an
important prognostic variable in patients with myelodysplastic syndromes (MDS) who are …

No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic
stem cell transplantation. We performed a retrospective registry analysis of outcomes and …

Background Allogeneic stem cell transplantation is usually considered the only curative
treatment option for patients with advanced or transformed myelodysplastic syndromes in …

The optimal bridge strategy at the decision for allogeneic hematopoietic stem cell
transplantation (HSCT) in patients with myelodysplastic syndrome (MDS) is unclear. We …

It has been suggested that bridging therapy with intensive chemotherapy and/or
hypomethylating agents followed by hematopoietic stem cell transplantation (HSCT) can be …

Approximately one-third of patients with myelodysplastic syndrome (MDS) receiving
allogeneic hematopoietic stem cell transplantation (HSCT) are cured by this treatment …

Despite new developments in innovative and potentially targeted drugs like hypomethylating
agents (HMA), allogeneic hematopoietic stem cell transplantation (HCT) is still the only …

The only potential cure for patients with myelodysplastic syndrome (MDS) is allogeneic
hematopoietic stem cell transplantation (HCT). However, a proportion of patients who are …

Patients diagnosed with myelodysplastic syndromes (MDS) often ask their physicians
whether earlier detection of disease or more prompt initiation of treatment might have …